Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0189 • ACR Convergence 2020
Determining the Relationship Between Mycobacterium Avium Subspecies Paratuberculosis Serostatus, Dietary Habits, Medication Regimen, and Joint Pain in Patients with Rheumatoid Arthritis
Chelsea Guan¹, Shazia Majid², Sweta Chalise², Saleh Naser², Robert Sharp² and Shazia Beg³, ¹University of Central Florida, Orlando, FL, ²University of Central Florida, Orlando, ³University of Central Florida College of Medicine, Orlando
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that primarily affects synovial tissues. While the exact etiology is unknown, it is hypothesized that…
Abstract Number: 0205 • ACR Convergence 2020
Methotrexate Therapy Is Not Associated with an Increased Risk of Liver Fibrosis Assessed by the Fibrosis-4 Index
Jerome Avouac¹, Raphael Degrave², Helene Vergneault¹ and Yannick Allanore¹, ¹Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, Ile-de-France, France
Background/Purpose: Methotrexate (MTX) holds a unique place in the management of rheumatoid arthritis (RA) given its favorable balance between efficacy and safety. However, conflicting data…
Abstract Number: 0221 • ACR Convergence 2020
Should We Use BioDMARDS in First Intention in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
Emilie Sapart¹, Tatiana Sokolova¹, Stéphanie de Montjoye¹, Stéphanie Dierckx², Adrien Nzeusseu Toukap³, Aleksandra Avramovska¹, Laurent Meric de Bellefon¹ and Patrick Durez⁴, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ³1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁴Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: Early effective treatment has led to major improvements in patients with rheumatoid arthritis (ERA). Low disease activity and remission are achieved earlier and in…
Abstract Number: 0238 • ACR Convergence 2020
Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort
Laura Gonzalez Hombrado¹, Marina Salido Olivares², Maria Carmen Ortega de la O³, Pilar Navarro Alonso⁴, Patricia Castro Perez⁵, Ana Castilla⁶, Alvaro Garcia Martos⁷, Celia Arconada³, Angel Aragon Diez⁸, Carolina Marin huertas³ and Eva Maria Andres Esteban⁹, ¹Hospital Universitario del Tajo, MADRID, Spain, ²Hospital de Parla, Madrid, Spain, ³Hospital infanta Elena, Madrid, Spain, ⁴Hospital de Fuenlabrada, Madrid, Madrid, Spain, ⁵Hospital Universitario de Getafe, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Hospital Universitario del Tajo, Madrid, ⁸Hospital Universitario de Gerafe, Madrid, Spain, ⁹Rey Juan Carlos University, Madrid, Spain
Background/Purpose: INTRODUCTION The use of biological therapies during pregnancy has been contraindicated since the beginning of the use of these drugs. In recent years several…
Abstract Number: 0482 • ACR Convergence 2020
Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Edward C Keystone¹, Mohammad Movahedi², Angela Cesta³, Claire Bombardier⁴, John Sampalis⁵ and Emmanouil Rampakakis⁵, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, ON, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada, ⁵JSS Medical Research, St-Laurent, QC, Canada
Background/Purpose: Treat-to-target recommendations for rheumatoid arthritis (RA) dictate that remission or low disease activity should be aimed. Although numerous composite indices are available, the clinical…
Abstract Number: 0576 • ACR Convergence 2020
Medical Savings of Timely Rheumatoid Arthritis Diagnoses
Kathryn Johnson¹, Christine Sawicki¹, Cristina Sotelo², Tanvi Kalevar³, Sylvie Lardeux⁴, Fabio Casadio³, David Baghdadi⁵, Michele Hamburger⁶, Elisea Avalos-Reyes⁷ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Austin, TX, ³CVS Health, New York, NY, ⁴CVS Health, Wellesley, MA, ⁵CVS Health, Woonsocket, RI, ⁶Frances Hamburger Institute, Hauppauge, NY, ⁷CVS Health, Irving, TX
Background/Purpose: Previous studies suggest that early rheumatoid arthritis (RA) recognition and treatment provides greater clinical benefits than treatment started later in the disease course. However,…
Abstract Number: 0747 • ACR Convergence 2020
Isotope-Labeling-LC-MS-based Metabolic Profiling of Multiple Serum Sample Sets for the Discovery of High-confidence Rheumatoid Arthritis Biomarkers
Xiaohang Wang¹, Wei Han¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is hampered by suboptimal accuracy of currently available serological biomarkers. In this work, we applied a high-performance chemical…
Abstract Number: 0764 • ACR Convergence 2020
Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data
Dmitry Rychkov¹, Jessica Neely¹ and Marina Sirota¹, ¹UCSF, San Francisco, CA
Background/Purpose: There is an urgent need to develop objective biomarkers for early diagnosis and monitoring of disease activity in Rheumatoid arthritis (RA). Here we define…
Abstract Number: 0781 • ACR Convergence 2020
Phenotypic and Functional Characterisation of Synovial Fluid-derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Ditte Køster¹, Johanne Hovgaard Egedal¹, Malene Hvid¹, Martin Roelsgaard Jakobsen¹, Ulf Müller-Ladner², Bent Deleuran¹, Tue Wenzel Kragstrup¹, Elena Neumann³ and Morten Aagaard Nielsen¹, ¹Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ³Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany
Background/Purpose: Fibroblast-like synoviocytes (FLS) are central cellular components in persistent inflammatory joint diseases such as rheumatoid arthritis (RA). Pathological subsets of FLS have been identified…
Abstract Number: 0798 • ACR Convergence 2020
A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92
Roy Fleischmann¹, Daniel Alvarez², Amy Bock³, Carol Cronenberger⁴, Ivana Vranic⁵, Wuyan Zhang⁶ and Rieke Alten⁷, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Pfizer, Collegeville, PA, ³Pfizer, Cambridge, MA, ⁴Pfizer, Collegeville, ⁵Pfizer, Tadworth, United Kingdom, ⁶Pfizer, New York, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany
Background/Purpose: To evaluate the long-term safety, immunogenicity (IG), and efficacy of the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF), in patients (pts) with moderate to severe active…
Abstract Number: 0814 • ACR Convergence 2020
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
Rishi Gupta¹, Muhammad Shipa², Su-Ann Yeoh², Pauline Buck¹ and Michael Ehrenstein², ¹University College London Hospital, London, United Kingdom, ²University College London, LONDON, United Kingdom
Background/Purpose: During the COVID-19 pandemic, rapid guidelines by the National Institute for Health and Care Excellence (NICE) in the United Kingdom[1] recommended consideration of switching…
Abstract Number: 0831 • ACR Convergence 2020
Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Age is an important factor that can affect disease course, physical function and treat to target strategy for patients with rheumatoid arthritis (RA). We…
Abstract Number: 0993 • ACR Convergence 2020
N-linked Glycosylation of the Immunoglobulin Variable Domain Affects Antigen Binding and Autoreactive B Cell Activation
Theresa Kissel¹, Changrong Ge², Lise Hafkenscheid¹, Linda Slot¹, Marco Cavallari³, Joanneke Kwekkeboom⁴, Manfred Wuhrer¹, Thomas Huizinga¹, Hans Scherer¹, Michael Reth³, Rikard Holmdahl² and René Toes¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Karolinska Institutet, Solna, Sweden, ³University Freiburg, Freiburg, Germany, ⁴Leiden Univeristy Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies, the hallmarking autoantibodies in Rheumatoid Arthritis (RA), are characterized by N-linked glycans in the variable domain (V-domain). The occurrence of these…
Abstract Number: 1013 • ACR Convergence 2020
National Burden of RA in Canada 1990-2017: Findings from the Global Burden of Disease Study 2017
Nejat Hassen¹, Diane Lacaille², Nizal Sarrafzadegan³, Alice Xu⁴, Sophia Sidi⁴, Amani Alandejani⁴, Marjan Mansourian⁵ and Jacek Kopec¹, ¹University of British Columbia, Arthritis Research Canada, Richmond, BC, Canada, ²University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, ³Isfahan University of Medical Sciences, University of British Columbia, Isfahan, Esfahan, Iran, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Isfahan University of Medical Sciences, Isfahan, Iran
Background/Purpose: It is estimated that over 120,000 individuals currently have rheumatoid arthritis (RA) in Canada, yet a comprehensive study summarizing the epidemiology of RA burden…
Abstract Number: 1184 • ACR Convergence 2020
In a Prospective RA Cohort, Higher Baseline Disease Activity Is an Independent Predictor of Decline in Left Ventricular Diastolic Function
Elizabeth Park¹, Kazato Ito², Christopher Depender¹, Jon Giles¹ and Joan Bathon¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY
Background/Purpose: Rheumatoid Arthritis (RA) patients are at nearly 50% increased risk of heart failure (HF) compared to non-RA patients, despite adjusting for the presence of…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].